Myriad Genetics Demonstrates Broad Utility of Precise MRD Assay Across Multiple Cancer Types at ASCO 2026
Event summary
- Myriad Genetics presented data from six poster sessions at the 2026 ASCO Annual Meeting, showcasing the clinical utility of its Precise MRD assay across diverse cancer types.
- The MONSTAR-SCREEN-3 study, led by Dr. Takayuki Yoshino, reported 97% baseline detection with 16% of samples detected in the ultrasensitive range.
- Post-surgical ctDNA positivity was strongly prognostic for recurrence risk, with ctDNA-positive patients showing significantly worse disease-free survival.
- Myriad highlighted the advantage of a whole-genome, personalized MRD approach in capturing clinically meaningful signals at the lowest ctDNA levels.
- The company will host an Industry Expert Theater session on May 31, 2026, to discuss the assay's technical details and clinical evidence.
The big picture
Myriad Genetics' presentation at ASCO 2026 underscores the growing importance of molecular residual disease (MRD) testing in oncology. The data supports the shift towards personalized, ultra-sensitive ctDNA monitoring, which could redefine recurrence risk assessment and treatment decision-making. As the precision medicine market expands, Myriad's ability to demonstrate broad clinical utility across multiple cancer types positions it as a key player in the diagnostic space.
What we're watching
- Clinical Adoption
- How the prognostic power of Precise MRD will drive its adoption in standard clinical practice for multiple cancer types.
- Regulatory Pathway
- Whether the data presented will accelerate regulatory approvals for Precise MRD in broader clinical settings.
- Competitive Positioning
- The pace at which Myriad can differentiate its assay from competitors in the rapidly evolving MRD testing market.
Related topics